Le Lézard
Classified in: Health, Business
Subject: CXP

Aphex BioCleanse Systems Inc, OTC, SNST, continuing to expand production at its new manufacturing location in Port Richey FL.


PITTSFORD, N.Y., Aug. 10, 2020 /PRNewswire/ -- Aphex BioCleanse Systems Inc. (OTC: SNST) announces today that the Company is continuing the buildout and expanding production of its revolutionary non-alcohol, non-toxic hydrogen based germ killing formula Hy-IQtm at its Port Richey Florida facility. The buildout design has been completed and General Contracting work will commence in the near future.

David J Weaver, CEO, says, "We have produced and shipped over two hundred 275 Gallon Totes since March of this year with our current manufacturing capacity. Once complete, the new manufacturing facility will allow us to produce up to 90 totes per day including Ready To Use (RTU) solution and also up to 10X Concentrate solutions for shipment in the United States and globally. The current pandemic crisis has significantly increased demand for non-alcohol sanitizing."

About Aphex BioCleanse Systems, Inc.

Aphex BioCleanse Systems Inc has developed a proprietary broad-based germ-killing formula trademarked as Hy-IQ tm Water. The Non-Toxic, Non-Alcohol, Hydrogen Based Trade Secret formulation has a unique method of action that uses hydrogen ions traveling at the speed of light to breach the cell walls of exoskeleton germs. Significant prior testing has proven the formula's ability to effectively kill a broad base of pathogens. "Hy-IQ, may be the most significant discovery in disinfecting since the discovery of chlorine in 1774," says Aphex CEO, David Weaver. www.aphexus.com 

FDA Statement

The statements in this document have not been evaluated or approved by the FDA. The products and statements referenced in this document are not intended to diagnose, treat, cure, or prevent any disease. 

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:


[email protected]


www.aphexus.com


Phone: 1-585-386-0990


Address:

Aphex BioCleanse Systems Inc.


15 Fishers Rd, #111


Pittsford, NY  14534

 

SOURCE Aphex BioCleanse Systems Inc.


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: